Therefore, targeting the CCL19/CCL21/CCR7 axis to inhibit lymphatic metastasis but maintaining a robust antitumor immune response has increasingly become a bright spot in tumor immunotherapy.209. This evidence concerns the gene CCL21 and neoplasm.